Chapter 26. Coactivators and Leukemia: The Acetylation Connection with Translocations Involving CBP, p300, TIF2, MOZ, and MLL
- Katya Ravid2,
- Jonathan D. Licht3
Published Online: 19 MAR 2002
DOI: 10.1002/0471223883.ch26
Copyright © 2001 by Wiley-Liss, Inc.
Book Title
Transcription Factors: Normal and Malignant Development of Blood Cells
Additional Information
How to Cite
Chinwalla, V. and Zeleznik-Le, N. J. (2002) Coactivators and Leukemia: The Acetylation Connection with Translocations Involving CBP, p300, TIF2, MOZ, and MLL, in Transcription Factors: Normal and Malignant Development of Blood Cells (eds K. Ravid and J. D. Licht), John Wiley & Sons, Inc., New York, USA. doi: 10.1002/0471223883.ch26
Editor Information
- 2
Department of Biochemistry, Boston University School of Medicine, Boston, MA
- 3
Derald H. Ruttenberg Cancer Center and Department of Medicine, Mount Sinai School of Medicine, New York, NY
Publication History
- Published Online: 19 MAR 2002
- Published Print: 15 DEC 2000
ISBN Information
Print ISBN: 9780471350545
Online ISBN: 9780471223887
- Summary
- Chapter
Keywords:
- leukemia;
- acetylation;
- translocations;
- CBP/p300 general coactivators;
- T1F2/nuclear receptor coactivators;
- histone acetyltransferases;
- MOZ-CBP fusion;
- mixed lineage leukemia (MLL);
- fusion coactivators
Summary
Transcriptional coactivators are molecules that act as bridges between the basal transcriptional machinery and transcription factors such as cAMP response element binding protein (CREB) and nuclear hormone receptors. Some transcriptional coactivators do not just simply act as bridging molecules, but rather have enzymatic functions of their own. Recently, the coactivators have also been linked directly to human disease: chromosomal translocations involving CBP/p300 and TIF2 are now implicated in causing particular types of acute myeloid leukemia. Here the authors review the literature that demonstrates the astounding association between coactivators and leukemia, and hypothesize about potential mechanisms whereby the novel fusion proteins produced by coactivator gene translocations could ultimately produce leukemia.